Antibiotic prescriptions in children with COVID-19 and Multisystem Inflammatory Syndrome: a multinational experience in 990 cases from Latin America

Background To date, there are no comprehensive data on antibiotic use in children with COVID 19 and Multisystem Inflammatory Syndrome (MIS C). Methods Multicenter cohort study from 5 Latin American countries. Children 17 years of age or younger with microbiologically confirmed SARSCoV2 infection or fulfilling MIS C definition were included. Antibiotic prescriptions were collected and factors associated with their use were calculated. Findings 990 children were included, with a median age of 3 years . Of these, 69 (7.0%) were diagnosed with MIS C. The prevalence of antibiotic use was 24.5% (n = 243). MIS-C with (OR = 45.48) or without (OR = 10.35) cardiac involvement, provision of intensive care (OR = 9.60), need for hospital care (OR = 6.87), pneumonia and/or ARDS detected through chest X rays (OR = 4.40), administration of systemic corticosteroids (OR = 4.39), oxygen support, mechanical ventilation or CPAP (OR = 2.21), pyrexia (OR = 1.84), and female sex (OR = 1.50) were independently associated with increased use of antibiotics. On the contrary, lower respiratory tract infections without radiologic evidence of pneumonia/ARDS and not requiring respiratory support (OR = 0.34) were independently associated with decreased use of antibiotics. There was significant variation in antibiotic use across the hospitals. Conclusions Our study showed a relatively high rate of antibiotic prescriptions in children with COVID 19 and in particular in those with severe disease or MIS C. Importantly, we found a significant variation in reasons for prescriptions of antibiotics and type of chosen therapies, as well in hospital practices, highlighting current uncertainties and lack of guidelines for the recognition of bacterial infections in children with COVID-19. Prospective studies are needed to provide better evidence on the recognition and management of bacterial infections in COVID 19 children.

[1]  Simon M. Lin,et al.  Assessment of 135 794 Pediatric Patients Tested for Severe Acute Respiratory Syndrome Coronavirus 2 Across the United States. , 2020, JAMA pediatrics.

[2]  S. Harbarth,et al.  Will coronavirus disease (COVID-19) have an impact on antimicrobial resistance? , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[3]  M. Simmaco,et al.  Impact of COVID-19 prevention measures on risk of health care-associated Clostridium difficile infection , 2020, American Journal of Infection Control.

[4]  R. Seaton,et al.  Survey of antibiotic and antifungal prescribing in patients with suspected and confirmed COVID-19 in Scottish hospitals , 2020, Journal of Infection.

[5]  R. Viner,et al.  Susceptibility to SARS-CoV-2 Infection Among Children and Adolescents Compared With Adults: A Systematic Review and Meta-analysis. , 2020, JAMA pediatrics.

[6]  M. Lenge,et al.  COVID-19 in 17 Italian Pediatric Emergency Departments , 2020, Pediatrics.

[7]  A. Holmes,et al.  Understanding the role of bacterial and fungal infection in COVID-19 , 2020, Clinical Microbiology and Infection.

[8]  S. Tibby,et al.  A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process , 2020, The Lancet Child & Adolescent Health.

[9]  D. Buonsenso,et al.  Pediatric Inflammatory Multisystem Syndrome Temporally Related With SARS-CoV-2: Immunological Similarities With Acute Rheumatic Fever and Toxic Shock Syndrome , 2020, Frontiers in Pediatrics.

[10]  A. Pantosti,et al.  Bacterial coinfections in COVID-19: an underestimated adversary. , 2020, Annali dell'Istituto superiore di sanita.

[11]  D. Buonsenso,et al.  COVID-19 and Multisystem Inflammatory Syndrome in Latin American Children , 2020, medRxiv.

[12]  Nina Singh,et al.  Antibiotic Consumption and Stewardship at a Hospital outside of an Early Coronavirus Disease 2019 Epicenter , 2020, Antimicrobial Agents and Chemotherapy.

[13]  P. Jorth,et al.  The Unrecognized Threat of Secondary Bacterial Infections with COVID-19 , 2020, mBio.

[14]  Felipe García,et al.  Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study , 2020, Clinical Microbiology and Infection.

[15]  D. Buonsenso,et al.  COVID-19 in South American Children: A Call For Action. , 2020, The Pediatric infectious disease journal.

[16]  Á. Avezum,et al.  Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 , 2020, The New England journal of medicine.

[17]  H. Donaldson,et al.  Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting , 2020, Clinical Microbiology and Infection.

[18]  C. Murray,et al.  COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study , 2020, The Lancet Child & Adolescent Health.

[19]  I. Jordan,et al.  Pediatric antimicrobial stewardship in the COVID-19 outbreak , 2020, Infection Control & Hospital Epidemiology.

[20]  P. Davies,et al.  Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. , 2020, JAMA.

[21]  G. Cooke,et al.  Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  B. Corrigan,et al.  Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID‐19 , 2020, Clinical pharmacology and therapeutics.

[23]  Zhongyi Jiang,et al.  Epidemiology of COVID-19 Among Children in China , 2020, Pediatrics.

[24]  Luke S P Moore,et al.  Antimicrobials: access and sustainable eff ectiveness 2 Understanding the mechanisms and drivers of antimicrobial resistance , 2015 .